13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          3504

          Background: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents have become available. Ultimately, strategy trials are needed to define the optimal use and the best sequencing of these agents. Methods: Patients with previously untreated RAS/BRAF wild-type unresectable mCRC were randomly assigned (1:1 ratio) to receive either FOLFIRI-cetuximab followed by mFOLFOX6-bevacizumab (arm A) or OPTIMOX-bevacizumab followed by FOLFIRI-bevacizumab followed by EGFR mab +/- irinotecan (arm B). This trial was designed as a superiority study (hypothesis arm B > arm A) with Duration of Disease Control (DDC) as primary endpoint, defined as the sum of PFS of each active sequence of treatment (Chibaudel B, J Clin Oncol, 2011). Secondary endpoints were overall survival (OS), Time to Failure of Strategy (TFS), Progression-free survival (PFS) and response rate (RECIST version 1.1) per sequence, salvage surgery rate, safety, and Quality of life (QoL). Results: Between October 2013 and May 2019, 263 eligible patients were randomized (arm A, n = 131; arm B, N = 132). After a median follow-up of 51.2 months (95% CI 43.3-57.4), 188 events for DDC were observed. Efficacy outcomes are presented in table. Median DDC was similar in both arms (HR 0.97, 95% CI 0.72-1.29; P = 0.805). Salvage surgery for metastasis (+/- radiofrequency ablation) was done in 36 (27.5%) patients in arm A and 28 (21.2%) in arm B. Median time until definitive deterioration of QoL (global health status) were 18.3 and 18.0 months (P = 0.628). The safety profiles were consistent with the established safety profiles of each treatment regimen. Conclusions: STRATEGIC-1 is the first randomized phase III study comparing multi-line standard treatment strategies in patients with KRAS/NRAS/BRAF wild-type mCRC. This study did not meet its primary endpoint of DDC. The treatment strategy starting with FOLFIRI-cetuximab followed by mFOLFOX6-bevacizumab led to higher response rates and to a trend for better median OS exceeding 3 years. These findings may add to our understanding of treatment sequencing in mCRC. Clinical trial information: NCT01910610. [Table: see text]

          Related collections

          Author and article information

          Journal
          Journal of Clinical Oncology
          JCO
          American Society of Clinical Oncology (ASCO)
          0732-183X
          1527-7755
          June 01 2022
          June 01 2022
          : 40
          : 16_suppl
          : 3504
          Affiliations
          [1 ]Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France;
          [2 ]Clinique Sainte-Anne, Strasbourg, France;
          [3 ]Department of Medical Oncology, Hopital Saint-Antoine, APHP, Paris, France;
          [4 ]Methodology and Quality of Life Unit in Oncology (INSERM UMR 1098), University Hospital of Besançon, Besançon, France;
          [5 ]Digestive Oncology, Hopital Duchenne, Boulogne-Sur-Mer, France;
          [6 ]Medical Oncology Department, Hôpital Privé des Côtes d'Armor, Plerin, France;
          [7 ]Cancerology Institute, Hôpital Privé Jean Mermoz, Lyon, France;
          [8 ]Pôle d'Oncologie Médicale, Groupe Hospitalier Public du Sud de l'Oise, Creil, France;
          [9 ]Clinique Victor Hugo, Le Mans, France;
          [10 ]Medical Oncology Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France;
          [11 ]Department of Medical Oncology, CH de Mont-de-Marsan, Hospital Layné, Mont-De-Marsan, France;
          [12 ]Medical Oncology Department, Institut Mutualiste Montsouris, Paris, France;
          [13 ]CH Annecy-Genevois, Annecy, France;
          [14 ]Medical Oncology Department, Lille Metropole Cancer Institute, Villeneuve D'ascq, France;
          [15 ]Medical Oncology Department Head, Henri Mondor University Hospital, Créteil, France;
          [16 ]Multidisciplinary Group in Oncology (GERCOR), Paris, France;
          [17 ]Cancer center, The Chaim Sheba Medical Center, Ramat Gan, Affiliated with the Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel;
          [18 ]Bon Secours Hospital Cork, Cancer Trials Ireland, and University College Cork, Cork, Ireland;
          [19 ]Medical Oncology Department, Centre Georges-François Leclerc, University of Bourgogne Franche-Comté, Dijon, France;
          Article
          10.1200/JCO.2022.40.16_suppl.3504
          253f9cd4-8e6c-4612-ae1a-0fdfe4c6430a
          © 2022
          History

          Comments

          Comment on this article